Eliquis
.5 mg · Tablet, for Suspension
- Prescription only
- Factor Xa Inhibitor
- Active substance
- Apixaban
- Used in
- Blood, clotting and anaemia
- Made by
- E.R. Squibb & Sons, L.L.C.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (ELIQUIS). It describes the substance, not this exact product.
Apixaban is a selective inhibitor of FXa.
It does not require antithrombin III for antithrombotic activity.
Apixaban is metabolized mainly via CYP3A4 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2.
Apixaban is eliminated in both urine and feces.
Food does not affect the bioavailability of apixaban.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-02-03
Safety of the active substance
From the US prescribing label for the same active substance (ELIQUIS). It describes the substance, not this exact product.
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.
- ELIQUIS is contraindicated in patients with the following conditions: Active pathological bleeding [see Warnings and Precautions (5.2) and Adverse Reactions (6.1) ] Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions) [see Adverse Reactions (6.1) ] Active pathological bleeding (4) Severe hypersensitivity to ELIQUIS (4)
Most common adverse reactions (>1%) are related to bleeding.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
BulgariaNo exact match for this strength and form
European UnionNo exact match for this strength and form
FranceNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | E.R. Squibb & Sons, L.L.C. |
|---|---|
| Active substance | Apixaban |
| Used in | Blood, clotting and anaemia |
| Strength | .5 mg |
| Form | Tablet, for Suspension |
| Route | Oral |
| Packs | 28 PACKET in 1 CARTON / 4 TABLET, FOR SUSPENSION in 1 PACKET · 28 PACKET in 1 CARTON / 1 TABLET, FOR SUSPENSION in 1 PACKET |
| NDC | 0003-1028 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Other strengths and forms
11 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- Tablet, Film Coated10 products
- Tablet, for Suspension1 products
- .5 mg
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.